Credit: Shutterstock photoRib-X Pharmaceuticals, a biotech developing new antibiotics for serious hospital and community infections, withdrew its plans for an initial public offering on Monday. The New Haven, CT-based company was founded in 2000 and booked $3 million in sales for the 12 months ended 12/31/2011. Deutsche Bank was set to be the bookrunner on the deal.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
